Kenneth T. Mills, President and CEO at REGENXBIO Inc. (RGNX), sold 45,000 shares at $19.69 ($886K) on 2023-12-19, disclosed to the SEC on 2023-12-21.
Scheduled sale ($886k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| RGNX | SELL | 2024-07-18 | $33K | — | Filing → |
| RGNX | SELL | 2024-05-16 | $237K | — | Filing → |
| RGNX | SELL | 2024-04-17 | $273K | — | Filing → |